Proficient in boring people about running Marathons, my dog Benson, gardening and non league football.
Pocklington
Joined May 2011
- Tweets14.9K
- Following435
- Followers1.1K
- Likes20.6K
$VKTX 12-18 months ahead on oral now.
Saving ….
2b design + startup: 3–4 months
•Enrolment: 4–6 months
•24–36 week treatment period
•Data readout + analysis: 3–4 months
•FDA meeting to align on Phase 3: 2–3 months
That’s roughly:
+12 to 18 months
$VKTX. Interesting that this new job went up at the weekend.
Senior clinical data manager
recruiting.paylocity.com/Rec…
$VKTX Full reversal from HIMs
“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims said”
From Apple News
$VKTX For me it’s interesting that this year the wording from Viking has changed from “Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 2 trial” to now saying
“Concurrently, the company is evaluating an oral formulation of VK2735 in obesity”
$VKTX clearly going straight to Ph 3
$VKTX onlinelibrary.wiley.com/doi/…
Looks like a full report on Venture just published
$VKTX literally hundreds of posts from this guy, since he first appeared spouting “single figures” and “FDA issues”.
Viking moved +46% since he started posting negatively.
That must hurt and is just stupid; money lost with every post.
@GMEshortsqueeze @Stocktwits @wallstreetbets $VKTX - April update they still use 12/31 cash balance, required by law to update 3/31. $95 to $19.85, CEO/CFO/COO delayed/drip data so they could dump their shares, 85 Inst buyers were deceived. Heading to single digit
$VKTX
Talk me out of this scenario:
VKtX release Ph2 on 26 Aug prior to 4 major pre planned Sept presentations which give BP opportunity to deal
All short reasons, obesity overcrowding, VKTX lateness, production, LLY/NVO superiority now flipped
TAM of $100bn+ sees $50bn BO
$VKTX
Cash deal (PFE, Merck, J&J) doesn’t need shareholder approval. Triggers immediate share price to BO price as 28m shares cover (26% of float) No rolling of short positions to acquirers stock. Immediate margin calls see short cover in open market and stock returned to lender
$VKTX. I seem to recall last year they went from 3000 to 2000 there were 15m shares that had to be sold (there are more funds tracking 3000 than 2000). This would appear to suggestViking have come out of 2000 to move to 3000, which means that stock would have to be repurchased
$VKTX Added to the Russell 3000.
Some will tell you this means nothing. Others will tell you it's fantastic news and that we will hit $30.
Personally I'm happy Ph.3 initiated last week and now look forward to Ph.2 oral data.
Data should normally be with us before summer ends.
$VKTX. Reads to me as though Viking have more than enough product “We have access to additional fill and finish capabilities of up to a hundred million annual units of vial and syringe product, as well as a hundred million units of auto injector product and also expandable….
$VKTX Ph3 starts this month AND “Another study that we’re really interested in getting going, and we’ll start it in the third quarter here, is to evaluate the PK when you transition somebody from a weekly dose to a monthly regimen. So this study will rapidly titrate” LIVE
$VKTX definitely analysts getting the move from subq to oral for maintenance and also combinations including VK2735, the latter which start next year
$Vktx so BL says license talks ongoing with 0214 and 2809 but won’t give commentary